Permira agreed to acquire a majority stake in Quotient Sciences, a global pharmaceutical development, clinical and commercial manufacturing organization, delivers innovative, customized solutions. Financial terms were not disclosed. “Quotient Sciences and its disruptive approach to pharmaceutical drug development have created a truly unique business model. With GHO’s support, the business has developed strongly in recent years and we look forward to partnering with Mark and his team in continuing to grow this exciting company,” Marcel Lacaze, Permira Principal.